Cancer Biology and Molecular Therapeutics

癌症生物学和分子治疗

基本信息

  • 批准号:
    7921845
  • 负责人:
  • 金额:
    $ 10.2万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2009
  • 资助国家:
    美国
  • 起止时间:
    2009-09-01 至 2011-08-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): This application requests continued support for a training program in Cancer Biology and Molecular Therapeutics that was begun in 1990. The program trains predoctoral and postdoctoral fellows in the fundamentals of cancer research by participation in didactic courses, seminars, discussion groups and performance of laboratory-based research. The training program is integrated into the research programs of the Morris Cotton Cancer Center, a National Cancer Institute-designated Comprehensive Cancer Center, thereby enhancing exposure to many facets of the disease. This is a multidisciplinary program drawing together 20 faculty with appointments in 7 different academic programs. The faculty have recently been brought together in a new Cancer Biology graduate program under an umbrella Program in Experimental and Molecular Medicine (PEMM). Predoctoral students are enrolled in the PEMM program in year 1 and then select one of five themes in which they undertake their thesis research, journal clubs and seminars. Students who select Cancer Biology then become the responsibility of the Cancer Biology Graduate Program for the remainder of their training. Required didactic work includes courses in Cancer Biology, Oncogenomics, and the Ethical Conduct of Research. Currently there are 43 PhD or MD/PhD students in the laboratories of the training faculty. Students are recruited to the Training Grant after they have completed one or more years in the graduate program, and have selected a faculty mentor. This allows their performance in first year classes and research rotations to be used as evidence of their potential to succeed in the PhD program. Postdoctoral trainees are engaged in fulltime research under the mentorship of a faculty adviser, but have their research experience broadened by regular interactions with other faculty and fellows through conferences, seminars and programmatic activities. There are currently 30 postdoctoral trainees in the laboratories of the faculty. Training grant funds are used to facilitate recruitment of postdoctoral trainees, who then are encouraged to obtain alternate extramural funding, thereby enhancing the ability of the program to recruit additional trainees. This mechanism also facilitates the recruitment of minority applicants as there is a more frequent turnover of positions, and hence funds can be assigned to any qualified minority as soon as identified. This training program has had an outstanding record of achievement since its inception, and this will be further strengthened by the focused training under the new Cancer Biology Graduate Program. This new direction for the program was achieved in major part by the established track record of this training program, and as a consequence we are requesting continued support at the current level of training positions.
描述(由申请人提供):本申请请求继续支持于1990年开始的癌症生物学和分子治疗学培训计划。该计划通过参加讲授课程、研讨会、讨论小组和基于实验室的研究的表现,在癌症研究的基础上培训博士后和博士后研究员。该培训计划被整合到莫里斯棉花癌症中心的研究计划中,该中心是国家癌症研究所指定的综合癌症中心,从而增加了对疾病许多方面的接触。这是一个多学科项目,汇集了7个不同学术项目的20名教职员工。教职员工最近被聚集在一个新的癌症生物学研究生项目中,该项目是在实验和分子医学(PEMM)的总体计划下进行的。博士前学生在一年级注册参加PEMM项目,然后从五个主题中选择一个,进行他们的论文研究、期刊俱乐部和研讨会。然后,选择癌症生物学的学生将成为癌症生物学研究生项目的责任,负责他们剩余的培训。要求的教学工作包括癌症生物学、肿瘤基因组学和研究的伦理行为等课程。目前,培训学院的实验室中有43名博士生或医学博士/博士生。学生在完成研究生课程的一年或多年后,并选择了一位教师导师,就被招募到培训补助金。这使得他们在第一年的课程和研究轮换中的表现可以被用作他们在博士项目中取得成功的潜力的证据。博士后实习生在教师顾问的指导下从事全职研究,但通过会议、研讨会和方案活动与其他教师和研究员进行定期互动,拓宽了他们的研究经验。目前,该学院实验室有30名博士后实习生。培训赠款资金用于促进招聘博士后受训人员,然后鼓励他们获得备选的外部资金,从而增强该方案招募更多受训人员的能力。这一机制还有助于招聘少数族裔申请者,因为职位更替更频繁,因此,一旦确定,就可以将资金分配给任何符合条件的少数族裔。这一培训计划自成立以来取得了突出的成绩,新的癌症生物学研究生计划下的重点培训将进一步加强这一点。该方案的这一新方向在很大程度上是通过该培训方案的既定记录实现的,因此,我们请求在当前级别的培训职位上继续提供支持。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

ALAN R EASTMAN其他文献

ALAN R EASTMAN的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('ALAN R EASTMAN', 18)}}的其他基金

MOLECULAR THERAPEUTICS RESEARCH PROGRAM
分子治疗研究计划
  • 批准号:
    7944597
  • 财政年份:
    2009
  • 资助金额:
    $ 10.2万
  • 项目类别:
Mechanisms of Resistance to Cell Cycle Checkpoint Kinase Inhibitors
细胞周期检查点激酶抑制剂的耐药机制
  • 批准号:
    7483072
  • 财政年份:
    2007
  • 资助金额:
    $ 10.2万
  • 项目类别:
Mechanisms of Sensitivity to Cell Cycle Checkpoint Kinase Inhibitors
对细胞周期检查点激酶抑制剂敏感的机制
  • 批准号:
    8633002
  • 财政年份:
    2007
  • 资助金额:
    $ 10.2万
  • 项目类别:
Mechanisms of Resistance to Cell Cycle Checkpoint Kinase Inhibitors
细胞周期检查点激酶抑制剂的耐药机制
  • 批准号:
    7629019
  • 财政年份:
    2007
  • 资助金额:
    $ 10.2万
  • 项目类别:
Mechanisms of Sensitivity to Cell Cycle Checkpoint Kinase Inhibitors
对细胞周期检查点激酶抑制剂敏感的机制
  • 批准号:
    9036264
  • 财政年份:
    2007
  • 资助金额:
    $ 10.2万
  • 项目类别:
Mechanisms of Resistance to Cell Cycle Checkpoint Kinase Inhibitors
细胞周期检查点激酶抑制剂的耐药机制
  • 批准号:
    7257577
  • 财政年份:
    2007
  • 资助金额:
    $ 10.2万
  • 项目类别:
Mechanisms of Resistance to Cell Cycle Checkpoint Kinase Inhibitors
细胞周期检查点激酶抑制剂的耐药机制
  • 批准号:
    7864084
  • 财政年份:
    2007
  • 资助金额:
    $ 10.2万
  • 项目类别:
Mechanisms of Sensitivity to Cell Cycle Checkpoint Kinase Inhibitors
对细胞周期检查点激酶抑制剂敏感的机制
  • 批准号:
    8499599
  • 财政年份:
    2007
  • 资助金额:
    $ 10.2万
  • 项目类别:
Mechanisms of Sensitivity to Cell Cycle Checkpoint Kinase Inhibitors
对细胞周期检查点激酶抑制剂敏感的机制
  • 批准号:
    9243917
  • 财政年份:
    2007
  • 资助金额:
    $ 10.2万
  • 项目类别:
Mechanisms of Resistance to Cell Cycle Checkpoint Kinase Inhibitors
细胞周期检查点激酶抑制剂的耐药机制
  • 批准号:
    8074512
  • 财政年份:
    2007
  • 资助金额:
    $ 10.2万
  • 项目类别:

相似国自然基金

Kidney injury molecular(KIM-1)介导肾小管上皮细胞自噬在糖尿病肾病肾间质纤维化中的作用
  • 批准号:
    81300605
  • 批准年份:
    2013
  • 资助金额:
    23.0 万元
  • 项目类别:
    青年科学基金项目
Molecular Plant
  • 批准号:
    31224801
  • 批准年份:
    2012
  • 资助金额:
    20.0 万元
  • 项目类别:
    专项基金项目
Molecular Interaction Reconstruction of Rheumatoid Arthritis Therapies Using Clinical Data
  • 批准号:
    31070748
  • 批准年份:
    2010
  • 资助金额:
    34.0 万元
  • 项目类别:
    面上项目
Molecular Plant
  • 批准号:
    31024802
  • 批准年份:
    2010
  • 资助金额:
    20.0 万元
  • 项目类别:
    专项基金项目
Cellular & Molecular Immunology
  • 批准号:
    30824806
  • 批准年份:
    2008
  • 资助金额:
    20.0 万元
  • 项目类别:
    专项基金项目

相似海外基金

Exploration of immunogenetic and molecular basis of hypertensive disease aiming at establishment of novel preventive and therapeutic strategies
探索高血压疾病的免疫遗传学和分子基础,旨在建立新的预防和治疗策略
  • 批准号:
    23K05615
  • 财政年份:
    2023
  • 资助金额:
    $ 10.2万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Molecular regulation and expression of Trop-2 in advanced prostate cancer: Identifying optimal therapeutic niches
晚期前列腺癌中 Trop-2 的分子调控和表达:确定最佳治疗领域
  • 批准号:
    10735996
  • 财政年份:
    2023
  • 资助金额:
    $ 10.2万
  • 项目类别:
Unveiling the molecular basis of chromatinopathies to delineate innovative therapeutic solutions
揭示染色质病变的分子基础,描绘创新的治疗解决方案
  • 批准号:
    EP/X027007/1
  • 财政年份:
    2023
  • 资助金额:
    $ 10.2万
  • 项目类别:
    Research Grant
Elucidation of molecular mechanisms related to smoking and inflammatory factors and establishment of novel therapeutic strategies for ARDS
阐明吸烟和炎症因子相关的分子机制并建立ARDS新的治疗策略
  • 批准号:
    23K08445
  • 财政年份:
    2023
  • 资助金额:
    $ 10.2万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Development of molecular targeted therapeutic measures against canine babesiosis
犬巴贝斯虫病分子靶向治疗措施的开发
  • 批准号:
    22KF0016
  • 财政年份:
    2023
  • 资助金额:
    $ 10.2万
  • 项目类别:
    Grant-in-Aid for JSPS Fellows
Molecular MR-PET to characterize malignant transformation and identify therapeutic vulnerabilities in human IDH-mutant gliomas
分子 MR-PET 表征人类 IDH 突变神经胶质瘤的恶性转化并确定治疗脆弱性
  • 批准号:
    10750893
  • 财政年份:
    2023
  • 资助金额:
    $ 10.2万
  • 项目类别:
Molecular Characteristics and Therapeutic Efficacy of PD-1 Inhibitors in MSI-H/dMMR Colorectal Cancer
PD-1抑制剂在MSI-H/dMMR结直肠癌中的分子特征和治疗效果
  • 批准号:
    23K15479
  • 财政年份:
    2023
  • 资助金额:
    $ 10.2万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Molecular mechanisms and structural determinants of pharmacological chaperone action; therapeutic potential for the treatment of early onset severe obesity
药理学伴侣作用的分子机制和结构决定因素;
  • 批准号:
    478493
  • 财政年份:
    2023
  • 资助金额:
    $ 10.2万
  • 项目类别:
    Operating Grants
Elucidation of the molecular mechanism of p53 stabilization of USP10 in hepatocellular carcinoma and development of novel therapeutic strategy
阐明p53稳定USP10在肝细胞癌中的分子机制并开发新的治疗策略
  • 批准号:
    23K15483
  • 财政年份:
    2023
  • 资助金额:
    $ 10.2万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Molecular mechanisms and therapeutic targeting of activated NRF2 signaling in MiT/TFE translocation renal cell carcinoma
MiT/TFE 易位肾细胞癌中激活的 NRF2 信号传导的分子机制和治疗靶向
  • 批准号:
    10633699
  • 财政年份:
    2023
  • 资助金额:
    $ 10.2万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了